Geron Investor Day
Please join Geron for an upcoming investor event focused on the Phase 3 development program and the potential commercialization of its first-in-class telomerase Inhibitor, imetelstat
The event will include a KOL panel discussing the unmet medical need of patients, in addition to the disease-modification potential of imetelstat
Featured KOLs will include: Dr. John Mascarenhas, Icahn School of Medicine, Mt. Sinai; Dr. Uwe Platzbecker, University Hospital, Leipzig; and Dr. Swaminathan Iyer, MD Anderson Cancer Center
The Geron Management Team will also discuss expanded development plans for imetelstat in new indications and in combination with other drugs
This Event Will Occur November 9, 2021 from 4:00 – 5:30 pm EST.
For more information or to RSVP, please contact Josh Rauch at jrauch@soleburytrout.com, or click here